BDKRB2
B2 bradykinin receptor
As of the edition of 20 October 2026, BDKRB2 (B2 bradykinin receptor, UniProt P30411) has 3 drugs tested at it and 3 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30411
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Heart and blood vessels; Immune system; Skin and connective tissue; Inherited and neonatal; Nervous system; Cancer; Infections; Bones, joints and muscles
- Registered trials of its drugs
- 29
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Icatibant | Marketed | Phase 4 | none listed |
| Labradimil | Went quiet | Phase 2 | none listed |
| Fasitibant | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Total on the list | 3 |
The other 0 companies at BDKRB2
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at BDKRB2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.